Peri A, Luciani P, Conforti B, Baglioni-Peri S, Cioppi F, Crescioli C, Ferruzzi P, Gelmini S, Arnaldi G, Nesi G, Serio M, Mantero F, Mannelli M
Endocrine Unit, Department of Clinical Physiopathology, University of Florence, 50139 Florence, Italy.
J Clin Endocrinol Metab. 2001 Nov;86(11):5443-9. doi: 10.1210/jcem.86.11.8042.
The molecular mechanisms leading to adrenocortical tumorigenesis have been only partially elucidated so far. Because the pituitary hormone ACTH, via activation of the cAMP pathway, regulates both cell proliferation/differentiation and steroid synthesis in the adrenal cortex, in this study we focused on the cAMP-dependent transcription factors cAMP responsive element modulator (CREM) and cAMP responsive element binding protein (CREB). We studied CREM and CREB expression by RT-PCR in human normal adrenal cortex (n = 3), adrenocortical adenomas (n = 8), and carcinomas (n = 8). We found transcripts corresponding to the isoforms alpha, beta, gamma, and tau2 of the CREM gene in all of the normal adrenal tissues, in the adenomas, and in seven of eight carcinomas. On the other hand, mRNA for the inducible cAMP early repressor isoforms, which derive from an internal promoter of CREM gene, was detected in the normal adrenal and in seven of eight adenomas, but in only three of eight carcinomas. Similarly, CREB transcripts were readily detectable in all normal adrenals and adenomas, whereas they were not found in four of eight adrenal carcinomas. To further characterize the carcinomas, telomerase activity and the expression of the ACTH receptor gene were determined. Telomerase activity in the carcinomas resulted in levels significantly higher than in the adenomas, whereas the levels of ACTH receptor mRNA were lower in the carcinomas. No correlation was found in the carcinomas between the levels of the ACTH receptor transcript and the loss of expression of CREB/inducible cAMP early repressor, suggesting that this alteration is not secondary to an upstream disregulation at the receptor level. In conclusion, our results suggest that an alteration in cAMP signaling may be associated with malignancies of the adrenal cortex.
到目前为止,导致肾上腺皮质肿瘤发生的分子机制仅得到了部分阐明。由于垂体激素促肾上腺皮质激素(ACTH)通过激活cAMP途径来调节肾上腺皮质中的细胞增殖/分化以及类固醇合成,因此在本研究中,我们重点关注了cAMP依赖性转录因子cAMP反应元件调节剂(CREM)和cAMP反应元件结合蛋白(CREB)。我们通过逆转录聚合酶链反应(RT-PCR)研究了CREM和CREB在人正常肾上腺皮质(n = 3)、肾上腺皮质腺瘤(n = 8)和癌(n = 8)中的表达情况。我们在所有正常肾上腺组织、腺瘤以及8例癌中的7例中发现了与CREM基因的α、β、γ和tau2亚型相对应的转录本。另一方面,在正常肾上腺以及8例腺瘤中的7例中检测到了源自CREM基因内部启动子的诱导型cAMP早期阻遏物亚型的mRNA,但在8例癌中仅在3例中检测到。同样,在所有正常肾上腺和腺瘤中都很容易检测到CREB转录本,而在8例肾上腺癌中的4例中未发现。为了进一步对癌进行特征描述,我们测定了端粒酶活性和促肾上腺皮质激素受体基因的表达。癌中的端粒酶活性水平显著高于腺瘤,而癌中促肾上腺皮质激素受体mRNA的水平较低。在癌中,促肾上腺皮质激素受体转录本水平与CREB/诱导型cAMP早期阻遏物表达缺失之间未发现相关性,这表明这种改变并非继发于受体水平的上游失调。总之,我们的结果表明cAMP信号传导的改变可能与肾上腺皮质恶性肿瘤有关。